While 81% of respondents had not personally observed complications in these patients, aspiration due to delayed gastric emptying and subsequently an increased aspiration risk was identified as the primary concern by the majority of respondents
Experimental evaluations demonstrated that the metal complex could efficiently catalyze the oxidation of glutathione (GSH) into glutathione disulfide (GSSG)
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
De Meyer GRY, Martinet W
Next review due: 18 Dec 2027 19 Jun 2023 | Latest version Last updated by Michael Stewart, MRPharmS Peer reviewed by Sid Dajani Ask, share, connect
This peptide selectively blocks N-type calcium channels in the spinal cord, providing pain relief for severe chronic pain without the tolerance and addiction risks of opioids